Quick Answer
CNS Pharmaceuticals, Inc. reported Shares Outstanding of 632.5 thousand shares for fiscal year 2025.
CNS Pharmaceuticals, Inc. Shares Outstanding — Annual History
| Fiscal Year | Shares Outstanding | YoY Change |
|---|---|---|
| 2025 | 632,516 | +437.0% |
| 2024 | 117,796 | +4638.4% |
| 2023 | 2,486 | -99.8% |
| 2022 | 1.62M | +70.4% |
| 2021 | 949,052 | -96.0% |
| 2020 | 23.86M | +45.0% |
| 2019 | 16.45M | +29.6% |
| 2018 | 12.69M | — |
Quarterly Shares Outstanding
| Quarter Ending | Shares Outstanding | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | 574,580 | -98.3% | +13.9% |
| June 30, 2025 | 504,413 | -65.1% | -82.9% |
| March 31, 2025 | 2.94M | -72.4% | +2399.6% |
| December 31, 2024 | 117,796 | -5.2% | -99.6% |
| September 30, 2024 | 33.45M | +695.0% | +2217.4% |
| June 30, 2024 | 1.44M | -65.1% | -86.5% |
| March 31, 2024 | 10.67M | +379.2% | +8482.8% |
| December 31, 2023 | 124,306 | -92.3% | -97.0% |
- CNS Pharmaceuticals, Inc. showed an increase of +437.0% in Shares Outstanding compared to the prior fiscal year.
- Over the 2018–2025 period, CNS Pharmaceuticals, Inc.’s shares outstanding has declined by 95.0% (from 12.69 million shares to 632.5 thousand shares).
- The most recent figure is from CNS Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: